OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
December 02, 2020
After a difficult year, bio/pharma science delivers promising results.
December 01, 2020
The expansion will include new suites for the development and clinical manufacturing of drug product intermediates and drug products and cGMP suites for early-phase cGMP manufacture.
November 30, 2020
The companies have entered into a global collaboration and license agreement to develop zuranolone (SAGE-217) for major depressive disorder, postpartum depression (PPD), and SAGE-324 for essential tremor and other neurological disorders.
November 24, 2020
Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.
November 19, 2020
Researchers concluded that the nasal spray should catch and coat the virus inside the nose, preventing it from spreading throughout the body, and it is then removed by nose-blowing or swallowing.
November 05, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
November 04, 2020
At the 2020 Bio/Pharma Virtual Congress, experts discuss the importance of characterizing excipients to ensure quality, safety, and effective performance.
Biopharma can apply new manufacturing practices adopted during the COVID-19 pandemic to enhance bioprocessing.
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
Biological and analytical advances enable modern fermentation processes to deliver safe and effective next-generation medicines.